Ryan Bitton, PharmD, MBA

A panel of experts share closing thoughts and advice for the management and uptake of HIV PrEP therapy.

Carl Schmid shares insight on the use of advocacy groups to help patients overcome barriers to access for HIV PrEP therapy.

Sean E. Bland, JD; Frank J. Palella, MD; and Carl Schmid explore organizational opportunities to improve access to HIV PrEP therapy and population health management strategies to improve PrEP uptake.

Carl Schmid discusses how the COVID-19 pandemic has amplified health care disparities and accessing HIV PrEP, and Frank J. Palella, MD, comments on the role of telehealth in improving access to PrEP.

Ryan Bitton, PharmD, MBA, provides a payer perspective on the importance of creating future health policies for HIV PrEP agents using real-world evidence and considering the total cost of care for patients.

Ryan Bitton, PharmD, MBA; Sean E. Bland, JD; Frank J. Palella, MD; and Carl Schmid comment on challenges in the implementation of USPSTF guidelines for HIV PrEP as well as existing unknowns with the guidance.

Frank J. Palella, MD, shares a provider perspective for steps to take in accordance with USPSTF guidelines for HIV PrEP to get patients appropriate medications, and Ryan Bitton, PharmD, MBA, shares a provider prospective on supporting expedited prior authorizations.

Sean E. Bland, JD, provides insight for when a health plan or issuer may use reasonable medical-management techniques, in accordance with USPSTF guidelines for HIV PrEP, and Ryan Bitton, PharmD, MBA, shares a payer perspective on utilization-management policies regarding PrEP.

Carl Schmid and Frank J. Palella, MD, discuss how coverage differs for medications vs ancillary service costs for HIV PrEP based on USPSTF guidelines.

Ryan Bitton, PharmD, MBA, and Frank J. Palella, MD, discuss facts about the implementation of USPSTF guidelines for HIV PrEP therapy.

Carl Schmid discusses the implications of the USPSTF Grade A rating of HIV PrEP to patients, providers, and payers.

Sean E. Bland, JD, reviews the USPSTF guidelines as support to access HIV PrEP therapy and Ryan Bitton, PharmD, MBA, shares a payer perspective on the implications of these guidelines.

Carl Schmid shares steps that providers and payers can take to overcome access barriers for HIV PrEP therapy.

Sean E. Bland, JD, discusses barriers to access for eligible patients to receive HIV PrEP therapy.

Carl Schmid and Frank J. Palella, MD, review unmet needs for the uptake of HIV PrEP therapy for at-risk patient populations.

Frank J. Palella, MD, and Ryan Bitton, PharmD, MBA, provide insight on the typical patient journey for someone who is going to receive HIV PrEP therapy and the recent increase in use of the therapy.

Experts in HIV provide closing thoughts on the future of PrEP, including improvement of uptake and addressing access disparities.

Key opinion leaders in HIV describe factors to consider when evaluating which patients may benefit from long-acting injectable PrEP therapies.

A multidisciplinary panel of experts discuss pipeline medications for PrEP and effects of the USPSTF grading on emerging therapies.

Experts in HIV provide insight into the Grade A recommendation for HIV PrEP by the U.S. Preventive Services Task Force (USPSTF) and its impact on patients, clinicians, and payers.

Key opinion leaders in HIV discuss nonadherence to HIV PrEP and methods to address patient “walk away.”

Ian Frank, MD and Jeffrey Crowley, MPH provide insight into engaging clinicians for increased assessment of patients for PrEP.

Experts in HIV discuss methods to address the low rate of HIV PrEP uptake among at-risk individuals.

A multidisciplinary panel of experts discuss challenges to monitoring patient adherence and persistence to HIV PrEP.

Ian Frank, MD and Jeffrey Crowley, MPH address HIV PrEP adherence and persistence issues in the clinical practice setting.

Experts in HIV provide insight into payer coverage of HIV PrEP and patient barriers for receiving PrEP.

Carl Schmid, MBA and Ian Frank, MD discuss the process of initiating HIV PrEP beginning with a clinical patient evaluation.

Ian Frank, MD and Jeffrey Crowley, MPH describe the CDC PrEP Care System Process and eligibility criteria for receiving PrEP.

A multidisciplinary panel of experts provides an overview of the economic burden of HIV and the role of pre-exposure prophylaxis (PrEP) in preventing HIV transmission.